文献速递其他结缔组织病

西班牙特发性炎症性肌病28年住院流行病学、自身免疫重叠与院内结局

Epidemiology, autoimmune overlap and in-hospital outcomes of idiopathic inflammatory myopathies in Spain, 1997-2024.
PubMed 文献 · Rheumatology (Oxford) · 2026-10-23

基于西班牙1997-2024年住院出院登记数据,分析特发性炎症性肌病(IIM)的住院率、自身免疫重叠及院内结局。真IIM占93.2%,住院率从1.67升至4.24/10万/年,限于≥60岁人群;死亡率为6.1%且稳定,死亡预测因素包括高龄、恶性肿瘤、心力衰竭、间质性肺病、吞咽困难和慢性肾脏病。

要点

  • IIM住院率28年间翻倍,增长限于60岁及以上人群。
  • 13.7%的IIM患者合并其他自身免疫病,约七分之一。
  • 死亡预测因素为高龄、恶性肿瘤、心衰、ILD、吞咽困难和CKD。

核心结论

  • IIM住院率在28年间翻倍,主要由免疫介导坏死性肌病识别增加和人口老龄化驱动。
  • 院内结局由急性并发症和合并症而非肌病亚型决定。

研究设计与样本

  • 基于西班牙医院出院登记(CMBD和RAE-CMBD)的人群分析,覆盖1997-2024年。
  • 共分析36 732例次住院,其中2016-2024年8053例患者,更早年份9162例患者。
  • 真IIM包括DM/PM组、IMNM/其他和IBM,并与症状性肌病编码(G73.7)区分。

主要发现

  • 34 228例次(93.2%)为真IIM,其中DM/PM组占84.0%(DM编码61.4%、PM编码35.7%、副肿瘤性2.9%),IMNM/其他占13.7%,IBM占2.4%。
  • 住院率从1.67/10万/年升至4.24/10万/年,增长限于≥60岁人群。
  • 合并其他自身免疫病者占13.7%,死亡率6.1%且保持稳定。
  • 死亡预测因素包括高龄(校正OR最高7.97)、恶性肿瘤、心力衰竭、间质性肺病、吞咽困难和慢性肾脏病(C统计量0.77)。
  • ICU入住率在高龄老人中下降(OR 0.21),提示 ceiling-of-care 降级;COPD和糖尿病的表观保护效应反映碰撞偏倚。

关键数值与推荐

  • DM/PM组中29.4%编码为多发性肌炎(M33.2),该比例从40%降至27%,此亚组ILD、重叠和抗合成酶特征更多而恶性肿瘤更少。
  • 死亡预测模型C统计量为0.77。
  • 高龄校正OR最高达7.97,ICU入住高龄OR为0.21。

临床怎么用

  • 临床应区分真IIM与症状性肌病编码,避免将后者纳入IIM分析。
  • 对高龄、合并恶性肿瘤、心衰、ILD、吞咽困难或CKD的IIM患者,应加强急性并发症和合并症管理。
  • 副肿瘤性皮肌炎应与特发性DM统一分析,而非单独编码。

局限性

  • 数据为住院率而非发病率或患病率。
  • 基于行政编码,可能存在编码偏倚和碰撞偏倚(如COPD和糖尿病的表观保护效应)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To define the epidemiology, autoimmune overlap and in-hospital outcomes of idiopathic inflammatory myopathies (IIM) in Spain, separating true IIM from the symptomatic-myopathy code (G73.7), and to identify predictors of mortality and intensive-care (ICU) admission. METHODS: Population-based analysis of the Spanish hospital-discharge registries (CMBD and RAE-CMBD, 1997-2024). Rates are hospitalization rates, not incidence or prevalence. True IIM comprised the DM/PM group (dermatomyositis, polymyositis and paraneoplastic DM codes), immune-mediated necrotizing myopathy/other (IMNM/Other) and inclusion body myositis (IBM). Estimates were verified against patient-clustered standard errors. RESULTS: Of 36 732 episodes (8053 patients in 2016-2024, 9162 earlier), 34 228 (93.2%) were true IIM (DM/PM group 84.0%: 61.4% DM-coded, 35.7% PM-coded, 2.9% paraneoplastic; IMNM/Other 13.7%, IBM 2.4%). Hospitalization rose from 1.67 to 4.24 per 100 000/year, confined to ages ≥60. Coexisting autoimmune disease occurred in 13.7% (about one in seven). Mortality was 6.1% and stable. Predictors of death were advancing age (adjusted OR up to 7.97), malignancy, heart failure, interstitial lung disease (ILD), dysphagia and chronic kidney disease (C-statistic 0.77); ICU admission fell in the very elderly (OR 0.21), indicating ceiling-of-care de-escalation. Apparent protective effects of COPD and diabetes reflected collider bias. Within the DM/PM group, 29.4% were coded as polymyositis (M33.2), with more ILD, overlap and antisynthetase features but less malignancy, declining from 40% to 27%. CONCLUSION: IIM hospitalizations doubled over 28 years, driven by IMNM recognition and ageing, with outcomes governed by acute complications and comorbidity rather than subtype. Symptomatic myopathy should be analysed separately and paraneoplastic dermatomyositis unified with idiopathic DM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Álvarez Troncoso J, Selva-O'Callaghan A, Gil Vila A, et al. Epidemiology, autoimmune overlap and in-hospital outcomes of idiopathic inflammatory myopathies in Spain, 1997-2024. Rheumatology (Oxford). 2026. PMID: 42920262. doi:10.1093/rheumatology/keag593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。